Key PointsAlthough the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite have soared under President Trump, it’s becoming increasingly difficult to sweep energy inflation under the rug.
(RTTNews) - Clinical-stage biotechnology company OSE Immunotherapeutics (OSE) reported a cash position of €11.1 million as of June 30, 2026, while highlighting progress across its oncology and immunology pipeline and reaffirming funding expected to support operations through Dece
(RTTNews) - NeuroSense Therapeutics Ltd. (NRSN), a late-stage clinical biotechnology company focused on treatments for neurodegenerative diseases, provided a business update and first-half 2026 financial results reflecting a narrower net loss.
The S&P 500 Index ($SPX ) (SPY ) closed up by +0.51% on Friday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.93%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.42%. December E-mini S&P futures (ESZ26 ) rose +0.47%, and December E-mini...
(RTTNews) - Burford Capital Limited (BUR, BUR.L) issued a statement regarding the verdict, in a case captioned Taction Technology, Inc. v. Apple Inc., which represents one of the largest patent verdicts in U.S. history. On September 25, a jury in a case in which Burford has a fin
(RTTNews) - Agfa-Gevaert (AGFB.BR), an imaging technology company, on Monday announced that it has entered into a definitive agreement with Electronics for Imaging to combine Agfa's Digital Printing Solutions business with EFI.
(RTTNews) - Kodiak Sciences Inc. (KOD), a pre-commercial, retina-focused biotechnology company, is expected to report topline results from DAYBREAK, a Phase 3 study evaluating both Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) in patients with wet age-relat
People (PPLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
(RTTNews) - Innovent Biologics, Inc. (1801.HK), a biopharmaceutical company focused on developing therapies across oncology and other major diseases, announced the expansion of the global Phase 3 MarsLight-11 study of IBI363/TAK-928 to include patients with non-squamous non-small